# Vaxart, Inc.: overview VXRT · OTC · CIK 72444 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/vxrt.md) · [Financials](/companies/vxrt/financials.md) · [Filings](/companies/vxrt/filings.md) · [Insiders](/companies/vxrt/insiders.md) Latest reported revenue: [$27.2m](/filings/0001437749-26-026289.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001437749-26-026289). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [4.9](/filings/0001437749-25-034840.md) | [15.2 d](/filings/0001437749-26-008023.md) | [20.9](/filings/0001437749-26-015608.md) | [39.7](/filings/0001437749-26-026289.md) | [72.4](/filings/0001437749-25-034840.md) | [104 d](/filings/0001437749-26-008023.md) | [39.2](/filings/0001437749-26-015608.md) | [27.2](/filings/0001437749-26-026289.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(293.4%)](/filings/0001437749-25-034840.md) | [(75.7%) d](/filings/0001437749-26-008023.md) | [(71.5%)](/filings/0001437749-26-015608.md) | [(36.8%)](/filings/0001437749-26-026289.md) | [(10.8%)](/filings/0001437749-25-034840.md) | [53.2% d](/filings/0001437749-26-008023.md) | [13.2%](/filings/0001437749-26-015608.md) | [(48.5%)](/filings/0001437749-26-026289.md) | | Net margin | % | [(285.4%)](/filings/0001437749-25-034840.md) | [(78.9%) d](/filings/0001437749-26-008023.md) | [(74.7%)](/filings/0001437749-26-015608.md) | [(37.7%)](/filings/0001437749-26-026289.md) | [(11.2%)](/filings/0001437749-25-034840.md) | [52.8% d](/filings/0001437749-26-008023.md) | [13.2%](/filings/0001437749-26-015608.md) | [(49.6%)](/filings/0001437749-26-026289.md) | | Diluted EPS | $ per share | not reported | not reported | [(0.07)](/filings/0001437749-26-015608.md) | not reported | not reported | not reported | [0.02](/filings/0001437749-26-015608.md) | not reported | | Free cash flow | $m | [(4.2) d](/filings/0001437749-25-034840.md) | [(7.4) d](/filings/0001437749-26-008023.md) | [(9.7)](/filings/0001437749-26-015608.md) | [(16.0) d](/filings/0001437749-26-026289.md) | [2.5 d](/filings/0001437749-25-034840.md) | [30.7 d](/filings/0001437749-26-008023.md) | [(2.5)](/filings/0001437749-26-015608.md) | [2.7 d](/filings/0001437749-26-026289.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.9](/filings/0001437749-23-006688.md) | [0.1](/filings/0001437749-24-007865.md) | [7.4](/filings/0001437749-25-008572.md) | [28.7](/filings/0001437749-26-008023.md) | [237](/filings/0001437749-26-008023.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(8156.1%)](/filings/0001437749-23-006688.md) | [(107090.7%)](/filings/0001437749-24-007865.md) | [(1129.5%)](/filings/0001437749-25-008572.md) | [(231.0%)](/filings/0001437749-26-008023.md) | [7.6%](/filings/0001437749-26-008023.md) | | Net margin | % | [(7900.2%)](/filings/0001437749-23-006688.md) | [(100708.4%)](/filings/0001437749-24-007865.md) | [(1117.6%)](/filings/0001437749-25-008572.md) | [(233.3%)](/filings/0001437749-26-008023.md) | [6.9%](/filings/0001437749-26-008023.md) | | Diluted EPS | $ per share | [(0.58)](/filings/0001437749-22-004354.md) | not reported | not reported | [(0.33)](/filings/0001437749-26-008023.md) | [0.07](/filings/0001437749-26-008023.md) | | Free cash flow | $m | [(65.0)](/filings/0001437749-23-006688.md) | [(104)](/filings/0001437749-24-007865.md) | [(72.3)](/filings/0001437749-25-008572.md) | [(45.3)](/filings/0001437749-26-008023.md) | [7.6](/filings/0001437749-26-008023.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vxrt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Heritage Wealth Advisors](/funds/1591122.md) | 2026-06-30 | $17.9k | 29,655 | | Unchanged | | [KINGSWOOD WEALTH ADVISORS, LLC](/funds/1987855.md) | 2026-06-30 | $6.1k | 10,005 | | New +10,005 | | [LVM CAPITAL MANAGEMENT LTD/MI](/funds/1053054.md) | 2026-06-30 | $15 | 25,000 | | Unchanged | | [Archer Investment Corp](/funds/1803804.md) | 2026-06-30 | $9 | 15 | | Unchanged | | [Archer Investment Corp](/funds/1803804.md) | 2026-06-30 | $9 | 15 | | Unchanged | ## Recent filings [All 1,172 filings](/companies/vxrt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 20:06 ET | [8-K](/filings/0001437749-26-032932.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-032932 | | 2026-09-14 | 20:05 ET | [8-K](/filings/0001437749-26-030318.md) | 8.01 Other events | 0001437749-26-030318 | | 2026-08-25 | 20:12 ET | [8-K](/filings/0001437749-26-028916.md) | 8.01 Other events | 0001437749-26-028916 | | 2026-08-06 | 20:23 ET | [10-Q](/filings/0001437749-26-026289.md) | Quarterly report, period 2026-06-30 | 0001437749-26-026289 | | 2026-08-06 | 20:17 ET | [8-K](/filings/0001437749-26-026280.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-026280 | | 2026-07-28 | 12:00 ET | [8-K](/filings/0001437749-26-024560.md) | 8.01 Other events | 0001437749-26-024560 | | 2026-07-17 | 20:10 ET | [8-K](/filings/0001437749-26-023762.md) | 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-023762 | | 2026-07-07 | 12:00 ET | [8-K](/filings/0001437749-26-022876.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-022876 | | 2026-07-02 | 10:20 ET | [8-K](/filings/0001213900-26-074576.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-074576 | | 2026-06-26 | 20:07 ET | [8-K](/filings/0001437749-26-021833.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-021833 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-008023.md), filed Mar 13, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9a5f4581-2523-4264-88cf-608ae2f6c329) ## About the filer - CIK: 72444 - Tickers: VXRT - Exchange: OTC - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:19 ET. No prices; not investment advice.